

MENJONG SORIG PHARMACEUTICALS CORPORATION LTD.
THIMPHU, BHUTAN

STATEMENT OF COMPREHENSIVE INCOME
for the Quarter ended 30th September, 2021

PARTICULARS	Note No.	QUARTER ENDED	QUARTER ENDED
		30/09/2021	30/09/2020
		(Nu.)	(Nu.)
REVENUE			
Sales	14	54,212,146.51	51,264,371.93
Other Income	15	1,448,799.12	318,023.00
Total Revenue		55,660,945.63	51,582,394.93
EXPENDITURE			
Changes in Finished Goods & Work-in-Progress	16	755,806.38	10,941,799.19
Raw Materials & Packaging Materials Consumed	17	21,018,755.01	22,740,952.42
Manufacturing Expenses	18	3,170,467.82	2,192,155.21
Employee Benefit Expenses	19	18,347,880.00	18,775,380.00
Finance Cost	20	4,629.85	160,512.00
Depreciation & Amortization	01	6,822,295.11	6,538,196.10
Other Expenses	21	3,003,952.13	2,320,362.19
Total Expenditure		53,123,786.31	63,669,357.11
Profit/(Loss) before Tax		2,537,159.32	(12,086,962.18)
Tax Expense			
Current Tax		-	-
Net Profit/(Loss) for the Year		2,537,159.32	(12,086,962.18)
Other comprehensive income			
<i>Items that will not be reclassified to profit or loss</i>			
Remeasurements of post-employment benefit obligations		-	-
Income tax relating to above item		-	-
Other comprehensive income, net of tax		-	-
Total comprehensive income		2,537,159.32	(12,086,962.18)
Earnings per equity share			
Basic and diluted			
Notes on Financial Statements forms integral part of Accounts	20	1.39	(6.63)

This is the Statement of Comprehensive Income referred to in our report of even date.

For Burman Singh & Associates
Chartered Accountants
FRN No: 326113E

Chairman

Chief Executive Officer

Ram Nath Singh
(Partner)
Mem.No-063418

Director

Place : THIMPHU

Date : , 2020

